• 한방재활의학과학회지
• /
• 제23권3호
• /
• pp.1-14
• /
• 2013

Objectives The object of this study was to observe the favorable anti-arthritic effects of Samki-eum ($s\bar{a}nq\grave{i}-y\check{i}n$) on Freund's complete adjuvant (FCA)-induced arthritic Wistar rats. Methods Rheumatoid arthritis was induced by intradermal injection of FCA, and 300, 150 or 750 mg/kg of Samki-eum ($s\bar{a}nq\grave{i}-y\check{i}n$) were orally administered once a day for 14 days from 14 days after FCA treatments, and 15 mg/kg of dexamethasone was intraperitoneally administered as reference drug in this experiment. All rats were sacrificed at 14 days after continuous oral treatment of Samki-eum ($s\bar{a}nq\grave{i}-y\check{i}n$) or intraperitoneal administration of dexamethasone, and changes on the body weight, knee circumferences, gross arthritis score, inflammatory tissue prostaglandin (PG) $E_2$ levels were monitored with cartilage collagen components and glucosaminoglycans compositions - chondroitin sulphate, heparan sulphate and hyaluronic acid in the present study. Results As results of FCA treatment, classic rheumatoid arthritis featuring dramatical decreases on the body weights, cartilage collagen contents and bone glucosaminoglycans-chondroitin sulphate, heparan sulphate and hyaluronic acid contents, with increases on the knee circumferences, gross arthritis scores and inflammatory tissue $PGE_2$ levels. However, these changes from FCA-induced rheumatoid arthritis were clearly reduced by treatment of dexamethasone and both two different dosages of Samki-eum ($s\bar{a}nq\grave{i}-y\check{i}n$) 300 and 150 mg/kg in the present study. Although FCA-induced arthritis were more favorably inhibited by treatment of dexamethasone 15 mg/kg as compared with Samki-eum ($s\bar{a}nq\grave{i}-y\check{i}n$) 300 mg/kg, marked decreases of body weights were detected in dexamethasone 15 mg/kg treated rats, and Samki-eum ($s\bar{a}nq\grave{i}-y\check{i}n$) 300 mg/kg showed similar preserve effects on the cartilage glucosaminoglycan compositions in this study. Conclusions The results obtained in this study suggest that over 300 and 150 mg/kg of Samki-eum ($s\bar{a}nq\grave{i}-y\check{i}n$) showed favorable anti-arthritic effects on the FCA-induced arthritis mediated by suppression of $PGE_2$, a inflammatory mediator. However, detail mechanism studies should be conduced in future with the screening of the biological active compounds in this herb. Although overall anti-inflammatory effects Samki-eum ($s\bar{a}nq\grave{i}-y\check{i}n$) 300 mg/kg were lowered than those of dexamethasone 15 mg/kg treated rats, Samki-eum ($s\bar{a}nq\grave{i}-y\check{i}n$) 300 mg/kg treated rats showed similar preserve effects on the cartilage glucosaminoglycan compositions in this experiment.

• Tuberculosis and Respiratory Diseases
• /
• 제58권5호
• /
• pp.498-506
• /
• 2005

연구배경 : 본 연구는 COPD환자를 대상으로 기관지확장제인 tiotropium 1일 1회, 1회 1캅셀 $18{\mu}g$과 ipratropium 1일 4회, 1회 2퍼프(퍼프당 $20{\mu}g$)의 유효성 및 안전성을 비교 평가하고자 하였다. 방 법 : 초기 선별방문 후, 환자는 2주간의 관찰기간에 들어갔으며, 이 기간을 마친 환자는 이중맹검, 무작위배정 하에 위약과 함께 1일 1회 tiotropium 또는 1일 4회 ipratropium을 투여 받았다. 유효성평가는 폐기능검사, 일중 PEFR측정, 환자평가 설문조사, 보조치료약물(살부타몰) 사용량으로 하였다. 폐기능검사는 치료시작 시(0일), 치료 14일후와 치료종료 시(28일)에 하였는데, 이때 투약 5분 전, 투약 후 30분, 60분, 120분 및 180분에 시행하였다. 결 과 : 16개 기관에서 134명의 환자가 분석되었다. 환자의 평균 (표준편차) 나이는 66 (7)세이었고 $FEV_1$은 예측치의 42 (12)%였다. 4주 치료 후 trough $FEV_1$ 반응은 ipratropium군에 비해 tiotropium군에서 유의하게 높았으며 PEFR경우에도 4주 동안 지속적으로 아침 흡입 전 측정한 PEFR이 tiotropium군에서 높게 나타났다(차이: 12.52-13.88 l/min). 4주 치료 기간동안 tiotropium은 좋은 내약성과 함께, ipratropium과 유사한 안전성을 나타냈다. 결 론 : 1일 1회 흡입용 항콜린제제인 tiotropium이 1일 4회 흡입용제제인 ipratropium에 비해 COPD환자를 치료하는데 더 우수한 기관지확장 반응을 보여주었고 안전성에서는 유사하였다.